

IGI LABORATORIES, INC  
Form 8-K  
May 28, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 27, 2015**

**IGI LABORATORIES, INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-08568</b>	<b>01-0355758</b>
<b>(State or other jurisdiction</b>	<b>(Commission File Number)</b>	<b>(IRS Employer</b>
<b>of incorporation)</b>		<b>Identification No.)</b>

**105 Lincoln Avenue  
Buena, New Jersey 08310  
(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (856) 697-1441**

---

**(Former Name or Former Address, if Changed Since Last Report)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):**

**☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

**☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Item 8.01. Other Events.**

On May 27, 2015, IGI Laboratories, Inc. (the “**Company**”) issued a press release announcing the Company’s updated financial guidance and business outlook for fiscal year 2015. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibit is filed with this Report:

**Exhibit No. Description**

99.1 Press release of IGI Laboratories, Inc. dated May 27, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IGI LABORATORIES, INC.**

Date: May 27, 2015 By: /s/ Jenniffer Collins  
Name: Jenniffer Collins  
Title: Chief Financial Officer